VCYT Veracyte Earnings and EPS analysis

Relative Growth: Rel. Growth: 87

Relative Strength: Rel. Strength: 84

Relative Valuation: Rel. Valuation: 45

Relative Profitability: Rel. Profitability: 90

EPS in 2026 (TTM): $1.11

Last Report Period Date: Mar 31, 2026

As of June 2026, VCYT's current EPS stands at $1.11, according to the latest financial reports. For the year 2025, the company recorded an earnings per share (EPS) of $0.84, which marks an increase compared to its EPS of $0.32 in 2024. VCYT reported an EPS of $0.36 for the quarterly report ending on Mar 31, 2026.

VCYT earnings history

Historical annual and quarterly earnings per share (EPS) data for Veracyte

EPS (TTM)

$1.11

EPS Growth YoY (Quarterly)

300%

EPS (Quarterly)

$0.36

EPS Growth (Quarterly)

-30.8%

For 2025, Veracyte's EPS was $0.84, an increase of 162.5% from $0.32 in 2024. For the fiscal quarter that ended on Mar 31, 2026, the per-share earnings was $0.36, showing a 300% increase from the same quarter last year. For the twelve months ending March 2026, the EPS is $1.11. For the year 2024, the yearly earnings per share was $0.32, marking an increase of 131.4% from 2023.

VCYT earnings chart

VCYT EPS growth history

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

300%

EPS growth YoY

162.5%

EPS growth 3Y avg

N/A

EPS growth 5Y avg

N/A

Veracyte has registered an increase in EPS of 300% during the last 12 months (YoY, quarterly).

VCYT Earnings Waterfall

Breakdown of revenue, profit and net income for Veracyte

VCYT Earnings vs Peers

What are the earnings of VCYT compared to its peers

Stock name	Price to Earnings	EPS grwoth 1Y	EPS grwoth 3Y	EPS grwoth 5Y
VCYT Veracyte Inc	44.98	162.5%	N/A	N/A
MYGN Myriad Genetics Inc	N/A	-180.1%	N/A	N/A
CYTK Cytokinetics Inc	N/A	-24.3%	N/A	N/A

All data is based on quarterly TTM periods, unless otherwise specified.